Ikarian Capital, LLC Ab Cellera Biologics Inc. Transaction History
Ikarian Capital, LLC
- $640 Million
- Q3 2025
A detailed history of Ikarian Capital, LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 73,700 shares of ABCL stock, worth $271,953. This represents 0.13% of its overall portfolio holdings.
Number of Shares
73,700Holding current value
$271,953% of portfolio
0.13%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ABCL
# of Institutions
169Shares Held
109MCall Options Held
1.26MPut Options Held
788K-
Baker Bros. Advisors LP New York, NY27.5MShares$102 Million1.13% of portfolio
-
Capital World Investors Los Angeles, CA13.4MShares$49.3 Million0.01% of portfolio
-
Baillie Gifford & CO10.4MShares$38.5 Million0.04% of portfolio
-
Two Sigma Investments, LP New York, NY5.18MShares$19.1 Million0.04% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny4.8MShares$17.7 Million0.05% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $1.05B
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...